Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung

Natalia Krawczyk; Tanja Fehm; Elmar Stickeler; Christoph Thomssen; Marc Thill; Franziska Fick; Achim Rody; Maggie Banys-Paluchowski

doi:10.1007/s00129-024-05219-9

Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung

Translated title of the contribution: Post(neo)adjuvant treatment concepts—Possibilities for individualization

Natalia Krawczyk^*, Tanja Fehm, Elmar Stickeler, Christoph Thomssen, Marc Thill, Franziska Fick, Achim Rody, Maggie Banys-Paluchowski

^*Corresponding author for this work

Abstract

Systemic breast cancer treatment is currently based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. For triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and nonpathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations, the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.

Translated title of the contribution	Post(neo)adjuvant treatment concepts—Possibilities for individualization
Original language	German
Journal	Gynakologie
Volume	57
Issue number	5
Pages (from-to)	273-281
Number of pages	9
ISSN	2731-7102
DOIs	https://doi.org/10.1007/s00129-024-05219-9
Publication status	Published - 05.2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-21 Gynaecology and Obstetrics

Access to Document

10.1007/s00129-024-05219-9

Cite this

@article{ccf03ffd0f4f47798495d56affeb56e3,

title = "Post(neo)adjuvante Therapiekonzepte – M{\"o}glichkeiten der Individualisierung",

abstract = "Systemic breast cancer treatment is currently based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. For triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and nonpathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations, the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.",

author = "Natalia Krawczyk and Tanja Fehm and Elmar Stickeler and Christoph Thomssen and Marc Thill and Franziska Fick and Achim Rody and Maggie Banys-Paluchowski",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2024.",

year = "2024",

month = may,

doi = "10.1007/s00129-024-05219-9",

language = "Deutsch",

volume = "57",

pages = "273--281",

journal = "Gynakologie",

issn = "2731-7102",

publisher = "Springer Medizin",

number = "5",

}

TY - JOUR

T1 - Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung

AU - Krawczyk, Natalia

AU - Fehm, Tanja

AU - Stickeler, Elmar

AU - Thomssen, Christoph

AU - Thill, Marc

AU - Fick, Franziska

AU - Rody, Achim

AU - Banys-Paluchowski, Maggie

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2024.

PY - 2024/5

Y1 - 2024/5

N2 - Systemic breast cancer treatment is currently based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. For triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and nonpathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations, the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.

AB - Systemic breast cancer treatment is currently based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. For triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and nonpathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations, the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.

UR - https://www.scopus.com/pages/publications/85190793782

U2 - 10.1007/s00129-024-05219-9

DO - 10.1007/s00129-024-05219-9

M3 - Zeitschriftenaufsätze

AN - SCOPUS:85190793782

SN - 2731-7102

VL - 57

SP - 273

EP - 281

JO - Gynakologie

JF - Gynakologie

IS - 5

ER -